<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01786252</url>
  </required_header>
  <id_info>
    <org_study_id>Endo-hCG-755</org_study_id>
    <secondary_id>IRB 12-755F</secondary_id>
    <nct_id>NCT01786252</nct_id>
  </id_info>
  <brief_title>Effect of hCG on Receptivity of the Human Endometrium</brief_title>
  <official_title>The Effect of hCG on the Human Endometrium</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Michigan State University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Michigan State University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Worldwide, 1 in 12 couples experience difficulty in getting pregnant and seek the help of
      assisted reproductive technologies (ART) such as in vitro fertilization (IVF-egg is
      fertilized by sperm outside the body), ovarian stimulation (medications are used to stimulate
      egg development) and intra-cytoplasmic injection (ICSI-single sperm is injected directly into
      the egg).

      Regardless of the ART procedure being performed, the newly fertilized embryo must still
      implant into the mothers endometrium (inner lining of uterus). This implantation process in
      humans is surprisingly inefficient and accounts for up to 50% of ART failures. Intrauterine
      infusion of hCG prior to embryo transfer has recently been shown to increase pregnancy rates
      but the cellular mechanism for this increase is unknown.

      Successful implantation requires the newly fertilized embryo and the endometrium develop in a
      synchronized manner. This coordinated development is accomplished, in part, by proteins
      secreted by the embryo which circulate throughout the maternal bloodstream and alert the
      maternal body organs (i.e. ovary, endometrium, breast, ect) that fertilization has occurred.

      One of the earliest of these secreted proteins is human chorionic gonadotropin (hCG), which
      is the molecule detected in over-the-counter pregnancy tests. From previous studies, we know
      that hCG production by the embryo alerts the ovary to continue producing progesterone, a
      hormone required for pregnancy. However, very little is known about the direct effect of hCG
      on the endometrium during early pregnancy in humans.

      Using animal models, hCG has been shown to induce specific changes in the endometrium,
      suggesting that embryo-derived hCG may be &quot;priming&quot; the endometrium in anticipation of
      implantation. The goal of this research study is to examine the direct effect of hCG on the
      human endometrium and see if this &quot;priming effect&quot; is also present in humans. Findings from
      this research may reveal whether pre-treatment with hCG can enhance ART outcomes, especially
      pregnancy rates.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Embryo implantation in humans is surprisingly inefficient and represents a major limiting
      factor for enhancement of ART success rates (ref 1-2). Successful implantation requires
      synchronized development between the newly fertilized embryo and the maternal endometrium
      within a specific window of time. In mammals, this coordinated development is accomplished,
      in part, by embryonic secretions which alert the body that fertilization has occurred.

      One of the earliest proteins produced by the embryo is human chorionic gonadotropin (hCG).
      Previous research has shown that hCG maintains progesterone production by the ovary, a
      hormone required for the maintenance of pregnancy. However, very little is known about the
      direct effect of hCG on the human endometrium. Our laboratory has previously shown that
      intrauterine infusion of hCG in the non-human primate can induce endometrial changes that
      mimic the initial stages of early pregnancy (i.e. altered cellular morphology, pre-decidual
      response and increased glandular activity; ref 3-4). These results suggest that
      embryo-derived hCG may also act directly upon the endometrium to &quot;prime&quot; it in anticipation
      of implantation. Research from other labs examining the effect of hCG on endometrial genes in
      vitro support this hypothesis (ref: 5-9). Additionally, a recent study of women undergoing
      ART revealed significantly increased implantation and pregnancy rates when the embryo
      transfer was preceded by intra-uterine infusion of 500IU hCG (ref 10).

      The purpose of this study is to determine whether the endometrial response to hCG seen
      previously in our non-human primate model is also present in women and to characterize this
      effect. Women who plan to undergo controlled ovarian stimulation for the purpose of egg
      donation will be eligible to participate in this research. Subjects in experimental group
      will receive a single intrauterine infusion of hCG (500IU) diluted in IVF media 3 days after
      oocyte retrieval. Control subjects will receive a single intrauterine infusion of IVF media
      only. Two days after infusion, both experimental group and control participants will return
      to the clinic where a sample of endometrial tissue will be obtained via pipelle biopsy and a
      sample of uterine secretory proteins will be obtained via uterine lavage. The uterine lavage
      samples will be examined using ELISA/proteomic analysis to determine the effect of hCG on
      uterine protein secretions. One portion of the endometrial biopsy will be formalin-fixed and
      paraffin-embedded for analysis of morphological and structural changes following hCG
      exposure. The second portion will be used for cellular and molecular analysis to determine
      the effect of hCG on genes and proteins of interest.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Actual">March 2016</completion_date>
  <primary_completion_date type="Actual">March 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Endometrial Staging in hCG Versus Vehicle Treated Patients</measure>
    <time_frame>2 days following infusion of hCG or IVF media</time_frame>
    <description>All H&amp;E-stained endometrial biopsies were analyzed in a blinded manner for endometrial dating and glandular and stromal development. Criteria for endometrial dating included the presence or absence of sub-nuclear vacuoles, which is one of the more reproducible features of the Noyes dating criteria. For the purposes of statistical analysis, the most advanced elements in each of the two endometrial compartments were considered. Data are specifically reported as days post-ovulation induction.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Expression of hCG Target NOTCH1 Protein by IHC in Endometrial Glands</measure>
    <time_frame>2 days following infusion of hCG or IVF media</time_frame>
    <description>Staining intensity of each section was quantified by image analysis software ImageJ (NIH) resulting in a Digital Histology Score (D-HSCORE), ranging from 0 to 255. Higher scores are associated with stronger staining/expression, while lower scores are the opposite.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Expression of hCG Target NOTCH1 Protein by IHC in Endometrial Stroma</measure>
    <time_frame>2 days following infusion of hCG or IVF media</time_frame>
    <description>Staining intensity of each section was quantified by image analysis software ImageJ (NIH) resulting in a Digital Histology Score (D-HSCORE), ranging from 0 to 255. Higher scores are associated with stronger staining/expression, while lower scores are the opposite.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Expression of hCG Target C3 Protein by IHC in Endometrial Stroma</measure>
    <time_frame>2 days following infusion of hCG or IVF media</time_frame>
    <description>Staining intensity of each section was quantified by image analysis software ImageJ (NIH) resulting in a Digital Histology Score (D-HSCORE), ranging from 0 to 255. Higher scores are associated with stronger staining/expression, while lower scores are the opposite.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Infertility</condition>
  <condition>Subfertility</condition>
  <arm_group>
    <arm_group_label>Drug: human chorionic gonadotropin (hCG)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: human chorionic gonadotropin (hCG). A single intrauterine infusion of 500IU hCG dissolved in IVF media (&quot;Global&quot;-trademark) will be administered to participants in the experimental group three days after oocyte retrieval. Two days after this infusion, participant will return to clinic where a uterine lavage and an endometrial biopsy will be performed to obtain a sample of uterine secretory proteins and endometrial tissue, respectively, for research analysis.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IVF media (&quot;Global&quot;-trademark)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo Comparator for hCG. A single intrauterine infusion of IVF media without hCG will be administered to participants in the control group three days after oocyte retrieval. Two days after this infusion, participant will return to clinic and a sample of uterine secretory proteins and endometrial tissue, will be obtained via uterine lavage and endometrial biopsy, respectively, for research analysis.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>human chorionic gonadotropin (hCG)</intervention_name>
    <description>500IU of hCG diluted to a final volume of 50ul in IVF media (&quot;Global&quot;-trademark)</description>
    <arm_group_label>Drug: human chorionic gonadotropin (hCG)</arm_group_label>
    <other_name>Novarel, human chorionic gonadotropin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Comparator (for hCG)</intervention_name>
    <description>50ul of IVF medium (&quot;Global&quot;-trademark) to mimic hCG infusion</description>
    <arm_group_label>IVF media (&quot;Global&quot;-trademark)</arm_group_label>
    <other_name>IVF media</other_name>
    <other_name>&quot;Global&quot; media-trademark</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. between the ages of 18-34 years old

          2. successfully applied for oocyte donor status at the Investigators Infertility clinic
             (The Fertility Center, 3230 Eagle Park Drive NE, suite 100. Grand Rapids MI 49525)

          3. meet the ASRM criteria for oocyte donation

        Exclusion Criteria:

          1. younger than 18 years old or older than 34 years old

          2. have not successfully applied for oocyte donor status at the Investigators Infertility
             clinic (The Fertility Center, 3230 Eagle Park Drive NE, suite 100. Grand Rapids MI
             49525)

          3. do not meet the ASRM criteria for oocyte donation
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>34 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Asgerally T. Fazleabas, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Michigan State University. Assistant Chair-Dept of Obstetrics, Gynecology&amp;Reproductive Biology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Fertility Center , 3230 Eagle Park Drive NE, suite 100</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49525</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Macklon NS, Geraedts JP, Fauser BC. Conception to ongoing pregnancy: the 'black box' of early pregnancy loss. Hum Reprod Update. 2002 Jul-Aug;8(4):333-43. Review.</citation>
    <PMID>12206468</PMID>
  </reference>
  <reference>
    <citation>Koot YE, Teklenburg G, Salker MS, Brosens JJ, Macklon NS. Molecular aspects of implantation failure. Biochim Biophys Acta. 2012 Dec;1822(12):1943-50. doi: 10.1016/j.bbadis.2012.05.017. Epub 2012 Jun 7. Review.</citation>
    <PMID>22683339</PMID>
  </reference>
  <reference>
    <citation>Fazleabas AT, Donnelly KM, Srinivasan S, Fortman JD, Miller JB. Modulation of the baboon (Papio anubis) uterine endometrium by chorionic gonadotrophin during the period of uterine receptivity. Proc Natl Acad Sci U S A. 1999 Mar 2;96(5):2543-8.</citation>
    <PMID>10051679</PMID>
  </reference>
  <reference>
    <citation>Banaszak S, Brudney A, Donnelly K, Chai D, Chwalisz K, Fazleabas AT. Modulation of the action of chorionic gonadotropin in the baboon (Papio anubis) uterus by a progesterone receptor antagonist (ZK 137. 316). Biol Reprod. 2000 Sep;63(3):820-5.</citation>
    <PMID>10952926</PMID>
  </reference>
  <reference>
    <citation>Banerjee P, Sapru K, Strakova Z, Fazleabas AT. Chorionic gonadotropin regulates prostaglandin E synthase via a phosphatidylinositol 3-kinase-extracellular regulatory kinase pathway in a human endometrial epithelial cell line: implications for endometrial responses for embryo implantation. Endocrinology. 2009 Sep;150(9):4326-37. doi: 10.1210/en.2009-0394. Epub 2009 Jun 25.</citation>
    <PMID>19556419</PMID>
  </reference>
  <reference>
    <citation>Sherwin JR, Sharkey AM, Cameo P, Mavrogianis PM, Catalano RD, Edassery S, Fazleabas AT. Identification of novel genes regulated by chorionic gonadotropin in baboon endometrium during the window of implantation. Endocrinology. 2007 Feb;148(2):618-26. Epub 2006 Nov 16.</citation>
    <PMID>17110430</PMID>
  </reference>
  <reference>
    <citation>Sherwin JR, Hastings JM, Jackson KS, Mavrogianis PA, Sharkey AM, Fazleabas AT. The endometrial response to chorionic gonadotropin is blunted in a baboon model of endometriosis. Endocrinology. 2010 Oct;151(10):4982-93. doi: 10.1210/en.2010-0275. Epub 2010 Jul 28.</citation>
    <PMID>20668030</PMID>
  </reference>
  <reference>
    <citation>Brosens JJ, Hodgetts A, Feroze-Zaidi F, Sherwin JR, Fusi L, Salker MS, Higham J, Rose GL, Kajihara T, Young SL, Lessey BA, Henriet P, Langford PR, Fazleabas AT. Proteomic analysis of endometrium from fertile and infertile patients suggests a role for apolipoprotein A-I in embryo implantation failure and endometriosis. Mol Hum Reprod. 2010 Apr;16(4):273-85. doi: 10.1093/molehr/gap108. Epub 2009 Dec 14.</citation>
    <PMID>20008415</PMID>
  </reference>
  <reference>
    <citation>Evans J, Catalano RD, Brown P, Sherwin R, Critchley HO, Fazleabas AT, Jabbour HN. Prokineticin 1 mediates fetal-maternal dialogue regulating endometrial leukemia inhibitory factor. FASEB J. 2009 Jul;23(7):2165-75. doi: 10.1096/fj.08-124495. Epub 2009 Mar 2.</citation>
    <PMID>19255255</PMID>
  </reference>
  <reference>
    <citation>Mansour R, Tawab N, Kamal O, El-Faissal Y, Serour A, Aboulghar M, Serour G. Intrauterine injection of human chorionic gonadotropin before embryo transfer significantly improves the implantation and pregnancy rates in in vitro fertilization/intracytoplasmic sperm injection: a prospective randomized study. Fertil Steril. 2011 Dec;96(6):1370-1374.e1. doi: 10.1016/j.fertnstert.2011.09.044. Epub 2011 Nov 1.</citation>
    <PMID>22047664</PMID>
  </reference>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 5, 2013</study_first_submitted>
  <study_first_submitted_qc>February 5, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 7, 2013</study_first_posted>
  <results_first_submitted>March 22, 2016</results_first_submitted>
  <results_first_submitted_qc>September 12, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 1, 2016</results_first_posted>
  <last_update_submitted>January 5, 2017</last_update_submitted>
  <last_update_submitted_qc>January 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Michigan State University</investigator_affiliation>
    <investigator_full_name>Asgerally Fazleabas</investigator_full_name>
    <investigator_title>Professor and Associate Chair, Department of Obstetrics,Gynecology+Reproductive Biology</investigator_title>
  </responsible_party>
  <keyword>embryo</keyword>
  <keyword>implantation</keyword>
  <keyword>blastocyst</keyword>
  <keyword>in vitro fertilization</keyword>
  <keyword>human chorionic gonadotropin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chorionic Gonadotropin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Drug: Human Chorionic Gonadotropin (hCG)</title>
          <description>Drug: human chorionic gonadotropin (hCG). A single intrauterine infusion of 500IU hCG dissolved in IVF media (&quot;Global&quot;-trademark) will be administered to participants in the experimental group three days after oocyte retrieval. Two days after this infusion, participant will return to clinic where a uterine lavage and an endometrial biopsy will be performed to obtain a sample of uterine secretory proteins and endometrial tissue, respectively, for research analysis.
human chorionic gonadotropin (hCG): 500IU of hCG diluted to a final volume of 50ul in IVF media (&quot;Global&quot;-trademark)</description>
        </group>
        <group group_id="P2">
          <title>IVF Media (&quot;Global&quot;-Trademark)</title>
          <description>Placebo Comparator for hCG. A single intrauterine infusion of IVF media without hCG will be administered to participants in the control group three days after oocyte retrieval. Two days after this infusion, participant will return to clinic and a sample of uterine secretory proteins and endometrial tissue, will be obtained via uterine lavage and endometrial biopsy, respectively, for research analysis.
Placebo Comparator (for hCG): 50ul of IVF medium (&quot;Global&quot;-trademark) to mimic hCG infusion</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Drug: Human Chorionic Gonadotropin (hCG)</title>
          <description>Drug: human chorionic gonadotropin (hCG). A single intrauterine infusion of 500IU hCG dissolved in IVF media (&quot;Global&quot;-trademark) will be administered to participants in the experimental group three days after oocyte retrieval. Two days after this infusion, participant will return to clinic where a uterine lavage and an endometrial biopsy will be performed to obtain a sample of uterine secretory proteins and endometrial tissue, respectively, for research analysis.
human chorionic gonadotropin (hCG): 500IU of hCG diluted to a final volume of 50ul in IVF media (&quot;Global&quot;-trademark)</description>
        </group>
        <group group_id="B2">
          <title>IVF Media (&quot;Global&quot;-Trademark)</title>
          <description>Placebo Comparator for hCG. A single intrauterine infusion of IVF media without hCG will be administered to participants in the control group three days after oocyte retrieval. Two days after this infusion, participant will return to clinic and a sample of uterine secretory proteins and endometrial tissue, will be obtained via uterine lavage and endometrial biopsy, respectively, for research analysis.
Placebo Comparator (for hCG): 50ul of IVF medium (&quot;Global&quot;-trademark) to mimic hCG infusion</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="7"/>
            <count group_id="B2" value="8"/>
            <count group_id="B3" value="15"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25.0" spread="0.976"/>
                    <measurement group_id="B2" value="26.3" spread="1.35"/>
                    <measurement group_id="B3" value="25.7" spread="3.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25.3" spread="3.8"/>
                    <measurement group_id="B2" value="23.3" spread="2.2"/>
                    <measurement group_id="B3" value="24.3" spread="3.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gravidity</title>
          <units>Number of times pregnant</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.43" spread="1.13"/>
                    <measurement group_id="B2" value="1.63" spread="1.30"/>
                    <measurement group_id="B3" value="1.53" spread="1.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Parity</title>
          <units>Number of deliveries</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.14" spread="1.07"/>
                    <measurement group_id="B2" value="1.25" spread="0.89"/>
                    <measurement group_id="B3" value="1.2" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Max E2 Level Prior to Oocyte Retrieval</title>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4097" spread="1112"/>
                    <measurement group_id="B2" value="4428" spread="1425"/>
                    <measurement group_id="B3" value="4274" spread="1255"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Average Ovulatory hCG Provided</title>
          <units>IU</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6429" spread="2440"/>
                    <measurement group_id="B2" value="7500" spread="2673"/>
                    <measurement group_id="B3" value="7000" spread="2535"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Cycle Length</title>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12.29" spread="0.76"/>
                    <measurement group_id="B2" value="13.25" spread="1.49"/>
                    <measurement group_id="B3" value="12.8" spread="1.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Oocytes Retrieved</title>
          <units>number of oocytes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19.1" spread="9.9"/>
                    <measurement group_id="B2" value="20.5" spread="8.1"/>
                    <measurement group_id="B3" value="19.9" spread="8.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Endometrial Staging in hCG Versus Vehicle Treated Patients</title>
        <description>All H&amp;E-stained endometrial biopsies were analyzed in a blinded manner for endometrial dating and glandular and stromal development. Criteria for endometrial dating included the presence or absence of sub-nuclear vacuoles, which is one of the more reproducible features of the Noyes dating criteria. For the purposes of statistical analysis, the most advanced elements in each of the two endometrial compartments were considered. Data are specifically reported as days post-ovulation induction.</description>
        <time_frame>2 days following infusion of hCG or IVF media</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Drug: Human Chorionic Gonadotropin (hCG)</title>
            <description>Drug: human chorionic gonadotropin (hCG). A single intrauterine infusion of 500IU hCG dissolved in IVF media (&quot;Global&quot;-trademark) will be administered to participants in the experimental group three days after oocyte retrieval. Two days after this infusion, participant will return to clinic where a uterine lavage and an endometrial biopsy will be performed to obtain a sample of uterine secretory proteins and endometrial tissue, respectively, for research analysis.
human chorionic gonadotropin (hCG): 500IU of hCG diluted to a final volume of 50ul in IVF media (&quot;Global&quot;-trademark)</description>
          </group>
          <group group_id="O2">
            <title>IVF Media (&quot;Global&quot;-Trademark)</title>
            <description>Placebo Comparator for hCG. A single intrauterine infusion of IVF media without hCG will be administered to participants in the control group three days after oocyte retrieval. Two days after this infusion, participant will return to clinic and a sample of uterine secretory proteins and endometrial tissue, will be obtained via uterine lavage and endometrial biopsy, respectively, for research analysis.
Placebo Comparator (for hCG): 50ul of IVF medium (&quot;Global&quot;-trademark) to mimic hCG infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Endometrial Staging in hCG Versus Vehicle Treated Patients</title>
          <description>All H&amp;E-stained endometrial biopsies were analyzed in a blinded manner for endometrial dating and glandular and stromal development. Criteria for endometrial dating included the presence or absence of sub-nuclear vacuoles, which is one of the more reproducible features of the Noyes dating criteria. For the purposes of statistical analysis, the most advanced elements in each of the two endometrial compartments were considered. Data are specifically reported as days post-ovulation induction.</description>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Endometrial Gland Dating</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0" spread="0.577"/>
                    <measurement group_id="O2" value="4.6" spread="0.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Endometrial Stroma Dating</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.9" spread="0.46"/>
                    <measurement group_id="O2" value="6.5" spread="0.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Statistical analysis to compare differences between endometrial glandular and stromal dating within the vehicle group.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>ANOVA</method>
            <method_desc>Sidak-multiple comparison test was performed to detect significant differences between groups.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Statistical analysis to compare differences between endometrial glandular and stromal dating within the hCG group.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>ANOVA</method>
            <method_desc>Sidak-multiple comparison test was performed to detect significant differences between groups.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Statistical analysis to compare stromal staging between hCG and IVF media group.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.01</p_value>
            <method>ANOVA</method>
            <method_desc>Sidak-multiple comparison test was performed to detect significant differences between groups.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Statistical analysis to compare differences between endometrial glandular dating between hCG and IVF media groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>ANOVA</method>
            <method_desc>Sidak-multiple comparison test was performed to detect significant differences between groups.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Expression of hCG Target NOTCH1 Protein by IHC in Endometrial Glands</title>
        <description>Staining intensity of each section was quantified by image analysis software ImageJ (NIH) resulting in a Digital Histology Score (D-HSCORE), ranging from 0 to 255. Higher scores are associated with stronger staining/expression, while lower scores are the opposite.</description>
        <time_frame>2 days following infusion of hCG or IVF media</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Drug: Human Chorionic Gonadotropin (hCG)</title>
            <description>Drug: human chorionic gonadotropin (hCG). A single intrauterine infusion of 500IU hCG dissolved in IVF media (&quot;Global&quot;-trademark) will be administered to participants in the experimental group three days after oocyte retrieval. Two days after this infusion, participant will return to clinic where a uterine lavage and an endometrial biopsy will be performed to obtain a sample of uterine secretory proteins and endometrial tissue, respectively, for research analysis.
human chorionic gonadotropin (hCG): 500IU of hCG diluted to a final volume of 50ul in IVF media (&quot;Global&quot;-trademark)</description>
          </group>
          <group group_id="O2">
            <title>IVF Media (&quot;Global&quot;-Trademark)</title>
            <description>Placebo Comparator for hCG. A single intrauterine infusion of IVF media without hCG will be administered to participants in the control group three days after oocyte retrieval. Two days after this infusion, participant will return to clinic and a sample of uterine secretory proteins and endometrial tissue, will be obtained via uterine lavage and endometrial biopsy, respectively, for research analysis.
Placebo Comparator (for hCG): 50ul of IVF medium (&quot;Global&quot;-trademark) to mimic hCG infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Expression of hCG Target NOTCH1 Protein by IHC in Endometrial Glands</title>
          <description>Staining intensity of each section was quantified by image analysis software ImageJ (NIH) resulting in a Digital Histology Score (D-HSCORE), ranging from 0 to 255. Higher scores are associated with stronger staining/expression, while lower scores are the opposite.</description>
          <units>D-HSCORE</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="111.9" spread="17.0"/>
                    <measurement group_id="O2" value="84.59" spread="17.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Expression of hCG Target NOTCH1 Protein by IHC in Endometrial Stroma</title>
        <description>Staining intensity of each section was quantified by image analysis software ImageJ (NIH) resulting in a Digital Histology Score (D-HSCORE), ranging from 0 to 255. Higher scores are associated with stronger staining/expression, while lower scores are the opposite.</description>
        <time_frame>2 days following infusion of hCG or IVF media</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Drug: Human Chorionic Gonadotropin (hCG)</title>
            <description>Drug: human chorionic gonadotropin (hCG). A single intrauterine infusion of 500IU hCG dissolved in IVF media (&quot;Global&quot;-trademark) will be administered to participants in the experimental group three days after oocyte retrieval. Two days after this infusion, participant will return to clinic where a uterine lavage and an endometrial biopsy will be performed to obtain a sample of uterine secretory proteins and endometrial tissue, respectively, for research analysis.
human chorionic gonadotropin (hCG): 500IU of hCG diluted to a final volume of 50ul in IVF media (&quot;Global&quot;-trademark)</description>
          </group>
          <group group_id="O2">
            <title>IVF Media (&quot;Global&quot;-Trademark)</title>
            <description>Placebo Comparator for hCG. A single intrauterine infusion of IVF media without hCG will be administered to participants in the control group three days after oocyte retrieval. Two days after this infusion, participant will return to clinic and a sample of uterine secretory proteins and endometrial tissue, will be obtained via uterine lavage and endometrial biopsy, respectively, for research analysis.
Placebo Comparator (for hCG): 50ul of IVF medium (&quot;Global&quot;-trademark) to mimic hCG infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Expression of hCG Target NOTCH1 Protein by IHC in Endometrial Stroma</title>
          <description>Staining intensity of each section was quantified by image analysis software ImageJ (NIH) resulting in a Digital Histology Score (D-HSCORE), ranging from 0 to 255. Higher scores are associated with stronger staining/expression, while lower scores are the opposite.</description>
          <units>D-HSCORE</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.66" spread="18.7"/>
                    <measurement group_id="O2" value="59.8" spread="15.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Expression of hCG Target C3 Protein by IHC in Endometrial Stroma</title>
        <description>Staining intensity of each section was quantified by image analysis software ImageJ (NIH) resulting in a Digital Histology Score (D-HSCORE), ranging from 0 to 255. Higher scores are associated with stronger staining/expression, while lower scores are the opposite.</description>
        <time_frame>2 days following infusion of hCG or IVF media</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Drug: Human Chorionic Gonadotropin (hCG)</title>
            <description>Drug: human chorionic gonadotropin (hCG). A single intrauterine infusion of 500IU hCG dissolved in IVF media (&quot;Global&quot;-trademark) will be administered to participants in the experimental group three days after oocyte retrieval. Two days after this infusion, participant will return to clinic where a uterine lavage and an endometrial biopsy will be performed to obtain a sample of uterine secretory proteins and endometrial tissue, respectively, for research analysis.
human chorionic gonadotropin (hCG): 500IU of hCG diluted to a final volume of 50ul in IVF media (&quot;Global&quot;-trademark)</description>
          </group>
          <group group_id="O2">
            <title>IVF Media (&quot;Global&quot;-Trademark)</title>
            <description>Placebo Comparator for hCG. A single intrauterine infusion of IVF media without hCG will be administered to participants in the control group three days after oocyte retrieval. Two days after this infusion, participant will return to clinic and a sample of uterine secretory proteins and endometrial tissue, will be obtained via uterine lavage and endometrial biopsy, respectively, for research analysis.
Placebo Comparator (for hCG): 50ul of IVF medium (&quot;Global&quot;-trademark) to mimic hCG infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Expression of hCG Target C3 Protein by IHC in Endometrial Stroma</title>
          <description>Staining intensity of each section was quantified by image analysis software ImageJ (NIH) resulting in a Digital Histology Score (D-HSCORE), ranging from 0 to 255. Higher scores are associated with stronger staining/expression, while lower scores are the opposite.</description>
          <units>D-HSCORE</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.3" spread="11.6"/>
                    <measurement group_id="O2" value="59.8" spread="21.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>IVF Media (&quot;Global&quot;-Trademark)</title>
          <description>Received IVF media infusion on Day 3 Post-Ovulation Induction</description>
        </group>
        <group group_id="E2">
          <title>Drug: Human Chorionic Gonadotropin (hCG)</title>
          <description>Received hCG infusion on Day 3 Post-Ovulation Induction</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Asgerally Fazleabas</name_or_title>
      <organization>Michigan State University</organization>
      <phone>(517) 884-6031</phone>
      <email>asgi@hc.msu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

